Stacey Dawn, Légaré France, Lewis Krystina, Barry Michael J, Bennett Carol L, Eden Karen B, Holmes-Rovner Margaret, Llewellyn-Thomas Hilary, Lyddiatt Anne, Thomson Richard, Trevena Lyndal
School of Nursing, University of Ottawa, 451 Smyth Road, Ottawa, ON, Canada.
Centre for Practice Changing Research, Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, ON, Canada, K1H 8L6.
Cochrane Database Syst Rev. 2017 Apr 12;4(4):CD001431. doi: 10.1002/14651858.CD001431.pub5.
Decision aids are interventions that support patients by making their decisions explicit, providing information about options and associated benefits/harms, and helping clarify congruence between decisions and personal values.
To assess the effects of decision aids in people facing treatment or screening decisions.
Updated search (2012 to April 2015) in CENTRAL; MEDLINE; Embase; PsycINFO; and grey literature; includes CINAHL to September 2008.
We included published randomized controlled trials comparing decision aids to usual care and/or alternative interventions. For this update, we excluded studies comparing detailed versus simple decision aids.
Two reviewers independently screened citations for inclusion, extracted data, and assessed risk of bias. Primary outcomes, based on the International Patient Decision Aid Standards (IPDAS), were attributes related to the choice made and the decision-making process.Secondary outcomes were behavioural, health, and health system effects.We pooled results using mean differences (MDs) and risk ratios (RRs), applying a random-effects model. We conducted a subgroup analysis of studies that used the patient decision aid to prepare for the consultation and of those that used it in the consultation. We used GRADE to assess the strength of the evidence.
We included 105 studies involving 31,043 participants. This update added 18 studies and removed 28 previously included studies comparing detailed versus simple decision aids. During the 'Risk of bias' assessment, we rated two items (selective reporting and blinding of participants/personnel) as mostly unclear due to inadequate reporting. Twelve of 105 studies were at high risk of bias.With regard to the attributes of the choice made, decision aids increased participants' knowledge (MD 13.27/100; 95% confidence interval (CI) 11.32 to 15.23; 52 studies; N = 13,316; high-quality evidence), accuracy of risk perceptions (RR 2.10; 95% CI 1.66 to 2.66; 17 studies; N = 5096; moderate-quality evidence), and congruency between informed values and care choices (RR 2.06; 95% CI 1.46 to 2.91; 10 studies; N = 4626; low-quality evidence) compared to usual care.Regarding attributes related to the decision-making process and compared to usual care, decision aids decreased decisional conflict related to feeling uninformed (MD -9.28/100; 95% CI -12.20 to -6.36; 27 studies; N = 5707; high-quality evidence), indecision about personal values (MD -8.81/100; 95% CI -11.99 to -5.63; 23 studies; N = 5068; high-quality evidence), and the proportion of people who were passive in decision making (RR 0.68; 95% CI 0.55 to 0.83; 16 studies; N = 3180; moderate-quality evidence).Decision aids reduced the proportion of undecided participants and appeared to have a positive effect on patient-clinician communication. Moreover, those exposed to a decision aid were either equally or more satisfied with their decision, the decision-making process, and/or the preparation for decision making compared to usual care.Decision aids also reduced the number of people choosing major elective invasive surgery in favour of more conservative options (RR 0.86; 95% CI 0.75 to 1.00; 18 studies; N = 3844), but this reduction reached statistical significance only after removing the study on prophylactic mastectomy for breast cancer gene carriers (RR 0.84; 95% CI 0.73 to 0.97; 17 studies; N = 3108). Compared to usual care, decision aids reduced the number of people choosing prostate-specific antigen screening (RR 0.88; 95% CI 0.80 to 0.98; 10 studies; N = 3996) and increased those choosing to start new medications for diabetes (RR 1.65; 95% CI 1.06 to 2.56; 4 studies; N = 447). For other testing and screening choices, mostly there were no differences between decision aids and usual care.The median effect of decision aids on length of consultation was 2.6 minutes longer (24 versus 21; 7.5% increase). The costs of the decision aid group were lower in two studies and similar to usual care in four studies. People receiving decision aids do not appear to differ from those receiving usual care in terms of anxiety, general health outcomes, and condition-specific health outcomes. Studies did not report adverse events associated with the use of decision aids.In subgroup analysis, we compared results for decision aids used in preparation for the consultation versus during the consultation, finding similar improvements in pooled analysis for knowledge and accurate risk perception. For other outcomes, we could not conduct formal subgroup analyses because there were too few studies in each subgroup.
AUTHORS' CONCLUSIONS: Compared to usual care across a wide variety of decision contexts, people exposed to decision aids feel more knowledgeable, better informed, and clearer about their values, and they probably have a more active role in decision making and more accurate risk perceptions. There is growing evidence that decision aids may improve values-congruent choices. There are no adverse effects on health outcomes or satisfaction. New for this updated is evidence indicating improved knowledge and accurate risk perceptions when decision aids are used either within or in preparation for the consultation. Further research is needed on the effects on adherence with the chosen option, cost-effectiveness, and use with lower literacy populations.
决策辅助工具是通过使患者的决策明确化、提供有关选择及其相关益处/危害的信息以及帮助阐明决策与个人价值观之间的一致性来支持患者的干预措施。
评估决策辅助工具对面临治疗或筛查决策的人群的影响。
在CENTRAL、MEDLINE、Embase、PsycINFO和灰色文献中进行更新检索(2012年至2015年4月);截至2008年9月还包括CINAHL。
我们纳入了已发表的随机对照试验,这些试验将决策辅助工具与常规护理和/或替代干预措施进行比较。对于本次更新,我们排除了比较详细决策辅助工具与简单决策辅助工具的研究。
两名评审员独立筛选纳入的文献、提取数据并评估偏倚风险。基于国际患者决策辅助工具标准(IPDAS)的主要结局是与所做选择和决策过程相关的属性。次要结局是行为、健康和卫生系统方面的影响。我们使用随机效应模型,通过均值差(MDs)和风险比(RRs)汇总结果。我们对使用患者决策辅助工具为咨询做准备的研究和在咨询过程中使用该工具的研究进行了亚组分析。我们使用GRADE评估证据的强度。
我们纳入了105项研究,涉及31043名参与者。本次更新增加了18项研究,并排除了28项之前纳入的比较详细决策辅助工具与简单决策辅助工具的研究。在“偏倚风险”评估中,由于报告不充分,我们将两项内容(选择性报告和参与者/人员的盲法)评为大多不明确。105项研究中有12项存在高偏倚风险。关于所做选择的属性,与常规护理相比,决策辅助工具增加了参与者的知识(MD 13.27/100;95%置信区间(CI)11.32至15.23;52项研究;N = 13316;高质量证据)、风险感知的准确性(RR 2.10;95%CI 1.66至2.66;17项研究;N = 5096;中等质量证据)以及知情价值观与护理选择之间的一致性(RR 2.06;95%CI 1.46至2.91;10项研究;N = 4626;低质量证据)。关于与决策过程相关的属性并与常规护理相比,决策辅助工具减少了因信息不足而产生的决策冲突(MD -9.28/100;95%CI -12.20至-6.36;27项研究;N = 5707;高质量证据)、对个人价值观的犹豫不决(MD -8.81/100;95%CI -11.99至-5.63;23项研究;N = 5068;高质量证据)以及决策中被动的人群比例(RR 0.68;95%CI 0.55至0.83;16项研究;N = 3180;中等质量证据)。决策辅助工具减少了未做决定的参与者比例,并且似乎对医患沟通有积极影响。此外,与常规护理相比,接触决策辅助工具的人对其决策、决策过程和/或决策准备的满意度相同或更高。决策辅助工具还减少了选择主要择期侵入性手术而倾向于更保守选择的人数(RR 0.86;95%CI 0.75至1.00;18项研究;N = 3844),但仅在排除关于乳腺癌基因携带者预防性乳房切除术的研究后,这种减少才达到统计学意义(RR 0.84;95%CI 0.73至0.97;17项研究;N = 3108)。与常规护理相比,决策辅助工具减少了选择前列腺特异性抗原筛查的人数(RR 0.88;95%CI 0.80至0.98;10项研究;N =